Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy
| Autor: | Lothar Schiller, Michael Rohde, Marianne Bernhart, Lukas Angleitner-Boubenizek, Ursula Pluschnigg, Jana Polachova, Tamara Hernler, Otto Gehmacher, August Zabernigg, Angelika Lanz-Veit, Wolfgang Stangl, Rene Schramböck, Kerstin Busch, Günther G. Steger, Uwe Kastner, Johannes Andel, Ralf Thödtmann, Edgar Petru |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Quinuclidines Time Factors Cyclophosphamide Vomiting Nausea medicine.drug_class medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Cancer Care Facilities chemistry.chemical_compound Sex Factors Bolus (medicine) Neoplasms Surveys and Questionnaires Product Surveillance Postmarketing medicine Humans Serotonin 5-HT3 Receptor Antagonists Antiemetic Adverse effect Aged Chemotherapy business.industry Palonosetron Age Factors General Medicine Middle Aged Isoquinolines Carboplatin chemistry Austria Anesthesia Practice Guidelines as Topic Antiemetics Female Serotonin Antagonists medicine.symptom business medicine.drug |
| Zdroj: | Wiener Medizinische Wochenschrift. 158:169-173 |
| ISSN: | 1563-258X 0043-5341 |
| DOI: | 10.1007/s10354-008-0515-1 |
| Popis: | BACKGROUND: Palonosetron is a new generation 5-HT3-receptor antagonist with a significantly prolonged half-life and a once-a-day administration compared to the conventional setrons. To evaluate the antiemetic efficacy of palonosetron in the daily hospital practice setting, a postmarketing study was carried out in Austria. METHODS: Palonosetron was administered at 0.25 mg on day 1 of each cycle to 135 cancer patients who received moderately or highly emetogenic chemotherapy either as an IV bolus or as a short-term infusion. Two thirds of these patients were females (n = 90), the majority had breast cancer (n = 38) and the majority received cisplatin, carboplatin, anthracyclines, 5-fluorouracil or cyclophosphamide. RESULTS: The complete antiemetic response rate was 68 % overall with 87 % efficacy on day 1 and 72 % efficacy on days 2 to 5. Higher antiemetic response was achieved in male patients, in patients being aged ≥ 50 years, and in chemonaive patients. Twenty-four percent of patients needed rescue medication. Only 1.5 % of patients reported mild adverse events. CONCLUSIONS: Palonosetron resulted in high antiemetic efficacy in this study. Female gender and age ≤ 50 years should be particularly considered when the antiemetic regimen is selected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink